Sign in
Not yet taking people in United StatesNo phase

Light therapy for pain and swelling in knee osteoarthritis

Tests a light therapy device against a sham device in people with knee osteoarthritis pain.

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Registry title
Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)
Status
Not yet recruiting
People taking part
30 people, planned
Started
Sept 2026
Expected to end
Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Photobiomodulation therapy (PBM) device
  • Sham PBM device
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 or older with painful knee osteoarthritis (wear-and-tear arthritis of the knee). It tests light therapy (PBM) against a sham device.

Age
50 Years to 99 Years
Sex
All sexes can join.
Disease stage
Knee osteoarthritis confirmed by a doctor using the American College of Rheumatology (ACR) criteria. Knee pain for ≥ 3 months. Average knee pain of ≥ 30/100 in a symptom diary and on the CATI scale.
Earlier treatment
No major surgery on the studied knee, such as knee replacement or osteotomy. No knee surgery in the past 6 weeks. No joint injection into the studied knee in the past 14 days. No daily opioids. No new pain medicine, pain therapy, chemotherapy or radiation started ≤ 30 days before screening.

Main reasons for not taking part

  • Active body-wide rheumatic disease, such as rheumatoid arthritis or lupus, or other pain worse than the knee pain.
  • Uncontrolled high blood pressure (SBP > 150 mmHg or DBP > 95 mmHg) or unstable heart or artery disease.
  • Neurological disease, stroke, serious mental illness, active suicidal thoughts, or substance-use disorder.
  • Skin problems at the treatment site, light-triggered migraine, or uncontrolled diabetes or its complications.
  • Pregnancy or breastfeeding, or memory or thinking problems that prevent consent.

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Clinically confirmed knee osteoarthritis (OA) based on the American College of Rheumatology (ACR) criteria with symptomatic pain for ≥ 3 months
  • Average knee-pain intensity ≥ 30/100 on both the Daily Symptom Diary (DSD) run-in and CATI
  • Age ≥ 50 years
  • Ability to give informed consent, attend visits, and complete ≥ 4 of 7 DSD entries pre-randomization
  • Capacity to perform all study tasks (Timed Up-and-Go, knee OA assessments, blood draw, questionnaires, etc)

Who cannot take part

  • Clinically significant surgery on the index knee (e.g., arthroplasty, osteotomy)
  • Knee surgery within the past 6 weeks
  • Intra-articular injection to the index knee within the past 14 days; Medication Use
  • Daily opioid therapy
  • New prescription or OTC analgesic, non-pharmacologic pain therapy, chemotherapy, or radiation therapy initiated ≤ 30 days before screening; Cardiovascular Safety
  • Systemic and Rheumatic Disease
  • Active systemic rheumatic condition (e.g., rheumatoid arthritis, systemic lupus erythematosus)
  • Hypersensitivity to PBM
  • Open wounds, skin infections, eczema, burns, or other dermatologic conditions at or near the treatment application site
  • Uncontrolled hypertension (SBP > 150 mmHg or DBP > 95 mmHg)
  • Unstable or activity-limiting cardiovascular or peripheral arterial disease; Neurological and Psychiatric Conditions
  • Diagnosed neurological disorder (e.g., Parkinson's disease, multiple sclerosis, epilepsy)
  • History or evidence of stroke or moderate-severe traumatic brain injury
  • Serious psychiatric illness requiring hospitalization within the past 12 months
  • Current substance-use disorder or past hospitalization for substance-use treatment; Dermatologic Conditions
  • Compromised skin integrity at or near the treatment site (e.g., open wounds, active rash, dermatitis, burns, ulcers, eczema, infection) interfering with topical treatment or PBM; Other Metabolic Conditions
  • Uncontrolled diabetes
  • Diabetes-related complications (e.g., peripheral neuropathy, severe nephropathy, chronic ulcers at treatment site); Other Pain Conditions
  • Cognitive impairment that precludes informed consent or task participation
  • Fibromyalgia with pain outside the knee that is equal to or worse than knee pain; Musculoskeletal History
  • Migraine triggered by light
  • Active suicidal ideation
  • Chronic pain at another body site more severe than knee pain; General Health and Cognition
  • Pregnancy or lactation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 99 years old?

Where in United States

  • University of FloridaGainesville, United StatesContact: Selenia Rubio, MD., MBANot yet recruiting

About the trial

What the trial wants to find out

This study aims to determine analgesic and anti-inflammatory effects of dual-wavelength PBM in people with symptomatic knee OA.

The 2 groups in the trial

  • Active PBMExisting treatment, for comparison

    Participants will receive active photobiomodulation (PBM) delivered to peri-articular knee sites, lumbar segments L2-L5, genicular/saphenous nerve fields, and lymphatic drainage zones using the THOR® LX2.3 device and study-specified treatment parameters. Treatment will be administered in six sessions over 2-3 weeks at a frequency of 2-3 sessions per week.

    Treatment: Photobiomodulation therapy (PBM) device

  • Sham PBMSham treatment, for comparison

    Participants will receive sham photobiomodulation (PBM) delivered using a visually identical THOR® LX2.3 device that does not emit therapeutic light. Sham treatment will be administered to the same anatomical sites and according to the same treatment schedule as the active PBM group, consisting of six sessions over 2-3 weeks at a frequency of 2-3 sessions per week.

    Treatment: Sham PBM device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis
Plain-language title
Light therapy for pain and swelling in knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07079969, who can take part
Record updated
20 August 2026